Pharmacy

The FDA Commissioner says that insurers can help biosimilar adoption by taking short-term financial losses over long-term drug savings. What else should they be doing?

At the 2019 Asembia Specialty Pharmacy Summit, Cardinal Health’s Bruce Feinberg articulates the pros and cons of copay accumulator programs.

The present and bright future of cholesterol treatments.

Patients taking heart medications are most at risk when a pharmacy shuts its doors.

The real-world strategies used to manage the high cost of specialty meds.

The Trump Administration has taken a large interest in PBM drug rebates, which they say create higher drug prices. But do they?

The stakes have never been higher in reducing readmissions and hospitals are leveraging pharmacists’ expertise and putting them at the forefront of readmission reduction programs

What health execs need to know about the drugs and policies affecting spending.

What the future of specialty drugs holds for healthcare.

A new HHS proposal could do away with-or at least forever change-PBM drug rebates. Here’s what that could mean for health execs.

Last year brought a variety of new treatments-and complications-for patients and payers. These five areas that defined 2018 will continue to define the future.

Each hospital and health system-and insurer-has unique circumstances, but there are several common approaches that are likely to help curb the growth in drug costs.

Here’s five things to take away from Anthem’s launch of PBM IngenioRx.

The concept of value-based care has begun to percolate through hospitals, doctor’s offices, and even Medicare, the behemoth of U.S. healthcare. It’s time for this principle to be embraced by PBMs.

While still largely a new phenomenon, biosimilars are here to stay-and this year will only bring more of them to market.

While the government shutdown doesn’t directly affect HHS, the shutdown is having profound and long-lasting effects on the U.S. healthcare system.

WalletHub released a study on Highest Drug Use by State to highlight the areas that stand to be most affected. Here are the top 10.

A look at what could be some of the biggest and most important drugs of the year.

Here are certain facts that every executive responsible for managing populations at risk for prescription drug misuse should know as they make policy decisions affecting patient care and financial management.

What experts say will be the year’s biggest problems, and what can be done about them.

Walgreens' new integrated support program aims to help patients with cancer manage the side effects of undergoing treatment. Here’s five things to know about it.

As pharmaceuticals grow to consume more and more of the healthcare dollar, traditional care models need to change in order to deliver the best healthcare outcomes and real value. Here are five new models on the rise.

A Managed Healthcare Executive’s cancer management survey revealed support for the selected use of complementary and alternative medicine. Where do things stand in what some consider a promising treatment area?

With all eyes on drug prices, payers are looking to biosimilar agents to cut costs-and improve patient outcomes.

In these arrangements, drug companies must partially reimburse insurers if the drug fails to earn its keep. Will COPD drugs be included in such arrangements?

Two recent studies on antibiotic use may indicate that antibiotic prescribing could be improving over time, but there’s room for improvement. Here’s four takeaways to get even better.

Despite a scolding from President Trump over drug price hikes, drug giant Pfizer announced it will raise the prices of 41 medications in January. That’s 10% of its entire drug portfolio.

This comprehensive, pay-for-performance approach drives clinical quality and affordability.

These products aid in treating several conditions, but are insurers paying for them? Find out.

Biosimilars hold great cost savings promises for payers and patients alike-but only if prescribers and patients are willing to make the switch.